Michael Kavanagh named Nanosonics CEO

Nanosonics (ASX:NAN) has tapped senior Cochlear (ASX:COH) executive Michael Kavanagh to become its next CEO.

Kavanagh will take the roles of CEO and president effective 21 October. He has been serving on the Nanosonics board since July last year.

Kavanagh is currently Cochlear’s senior vice president of global marketing. He has been working at the hearing aid implant company for 10 years and in the healthcare industry for the past 20.

“The last 12 months as a non-executive director has afforded me the opportunity to get to know the business, the talent and commitment of the team that’s in place and the nature of the global opportunity for the organisation,” he said.

Nanosonics’ current CEO, Ron Weinberger, will stay on with the company in the newly created role of president of technology development and commercialisation. He will also maintain a seat on the board of directors.

Nanosonics has been busy expanding its reach for flagship product Trophon EPR, an ultrasound probe disinfection cabinet system. In April, the company revealed it had doubled the number of probes certified for compatibility with the system.

That month, the company signed on a new UK distributor for Trophon EPR but revealed plans to also continue selling the cabinets into the market directly.

Nanosonics (ASX:NAN) shares were trading 1.11% lower at $0.89 as of around 2 pm on Tuesday.